10-QPeriod: Q2 FY2008

BRISTOL MYERS SQUIBB CO Quarterly Report for Q2 Ended Jun 30, 2008

Filed July 24, 2008For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb Company (BMY) reported strong financial results for the second quarter and first half of 2008. Net sales increased by 16% to $5.2 billion in the second quarter and 18% to $10.1 billion for the first half, driven by robust performance in the Pharmaceuticals segment, particularly key products like PLAVIX, ABILIFY, and the HIV portfolio. Net earnings from continuing operations saw a significant increase, reflecting strong sales growth and improved operational efficiencies, despite some restructuring charges related to the Productivity Transformation Initiative (PTI). The company is actively managing its business portfolio, announcing the sale of its ConvaTec business for approximately $4.1 billion and planning an IPO for its Mead Johnson Nutritionals segment. Strategic acquisitions, such as Kosan Biosciences, and pipeline advancements, including new regulatory submissions for diabetes treatments, demonstrate a continued focus on innovation and future growth. BMY also highlighted its strong liquidity position, with significant cash and cash equivalents, and reiterated its commitment to shareholder returns through dividends.

Financial Highlights

30 data points
Beta

Revenue

$5.20B

67.9% Gross Margin

Net Income

$764.00M

14.7% Net Margin

EPS (Diluted)

$0.38

Cash & Equivalents

$4.05B

Free Cash Flow

$1.43B

Financial Statements
Beta
Revenue$5.20B
Cost of Revenue$1.67B
Gross Profit$3.53B
R&D Expenses$826.00M
SG&A Expenses$1.17B
Operating Expenses$3.98B
Net Income$764.00M
EPS (Basic)$0.38
EPS (Diluted)$0.38

Key Highlights

  • 1Net sales increased by 16% to $5.2 billion in Q2 2008 and 18% to $10.1 billion in the first half of 2008, driven by strong pharmaceutical product sales.
  • 2Net earnings from continuing operations increased by 23% to $722 million in Q2 2008 and 16% to $1.37 billion in the first half of 2008.
  • 3The company announced the sale of its ConvaTec business for approximately $4.1 billion and plans for an IPO of its Mead Johnson Nutritionals segment, signaling portfolio optimization.
  • 4Key product sales showed strong growth: PLAVIX sales up 17% in Q2, ABILIFY up 28% in Q2, and BARACLUDE sales more than doubled in Q2.
  • 5Research and development expenses increased by 9% to $826 million in Q2 2008, supporting pipeline development and strategic partnerships.
  • 6The company generated $1.9 billion in net cash provided by operating activities for the first half of 2008.
  • 7Long-term debt increased to $6.0 billion from $4.4 billion at year-end 2007, mainly due to new debt issuances.

Frequently Asked Questions

The substantial increase in net sales was primarily driven by strong performance in the Pharmaceuticals segment, with key products like PLAVIX, ABILIFY, REYATAZ, and the SUSTIVA Franchise showing significant growth. Favorable foreign exchange rates also contributed to the sales increase.

BMY is actively managing its portfolio by divesting non-core assets and focusing on its biopharmaceutical business. This includes the announced sale of the ConvaTec business for $4.1 billion and plans to take its Mead Johnson Nutritionals segment public via an IPO. The company also completed the acquisition of Kosan Biosciences for $191 million to bolster its oncology pipeline.

The PLAVIX patent litigation remains ongoing, particularly concerning the U.S. patent ('265 Patent) and challenges from generic manufacturers like Apotex, Dr. Reddy's, Teva, and Cobalt. While a district court upheld the validity of the '265 Patent, Apotex's appeal is pending. Loss of market exclusivity for PLAVIX due to generic competition could be material to the company's sales and financial results.

Key risks include the potential for generic competition for PLAVIX in the US and European markets due to patent expirations and litigation outcomes. Additionally, the company faces ongoing litigation and investigations related to pricing, sales, and marketing practices. The company also notes potential impairments to its investment portfolio due to continuing uncertainties in credit and capital markets.